Great West Life Assurance Co. Can Boosts Holdings in MEDNAX, Inc. (NYSE:MD)


Share on StockTwits

Great West Life Assurance Co. Can lifted its stake in MEDNAX, Inc. (NYSE:MD) by 2.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 42,701 shares of the company’s stock after purchasing an additional 1,071 shares during the period. Great West Life Assurance Co. Can’s holdings in MEDNAX were worth $695,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the company. Paloma Partners Management Co bought a new position in shares of MEDNAX in the 3rd quarter worth about $947,000. Twinbeech Capital LP bought a new position in shares of MEDNAX in the 3rd quarter worth about $285,000. Voloridge Investment Management LLC increased its stake in shares of MEDNAX by 809.9% in the 3rd quarter. Voloridge Investment Management LLC now owns 105,354 shares of the company’s stock worth $1,715,000 after acquiring an additional 93,776 shares in the last quarter. Cubist Systematic Strategies LLC increased its stake in shares of MEDNAX by 134.2% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 202,704 shares of the company’s stock worth $3,300,000 after acquiring an additional 116,149 shares in the last quarter. Finally, Engineers Gate Manager LP increased its stake in shares of MEDNAX by 171.0% in the 3rd quarter. Engineers Gate Manager LP now owns 60,254 shares of the company’s stock worth $981,000 after acquiring an additional 38,017 shares in the last quarter. 93.85% of the stock is owned by hedge funds and other institutional investors.

MD opened at $23.06 on Thursday. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 2.16. The company has a market cap of $1.97 billion, a price-to-earnings ratio of -2.67, a PEG ratio of 1.90 and a beta of 2.03. The company’s 50 day moving average is $22.94 and its 200 day moving average is $18.96. MEDNAX, Inc. has a 12-month low of $7.37 and a 12-month high of $27.86.

MEDNAX (NYSE:MD) last posted its quarterly earnings data on Friday, November 6th. The company reported $0.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.04. The company had revenue of $460.60 million for the quarter, compared to the consensus estimate of $535.42 million. MEDNAX had a negative net margin of 26.57% and a positive return on equity of 12.27%. The firm’s revenue was up 1.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.91 earnings per share. As a group, analysts predict that MEDNAX, Inc. will post 1.21 EPS for the current fiscal year.

In other MEDNAX news, Director Roger Md Medel sold 66,806 shares of MEDNAX stock in a transaction that occurred on Wednesday, December 9th. The shares were sold at an average price of $23.00, for a total transaction of $1,536,538.00. Following the transaction, the director now owns 1,691,877 shares of the company’s stock, valued at $38,913,171. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 3.70% of the stock is owned by insiders.

Several brokerages recently issued reports on MD. TheStreet upgraded shares of MEDNAX from a “d” rating to a “c-” rating in a research note on Friday, November 13th. Truist raised their price objective on shares of MEDNAX from $20.00 to $26.00 in a research note on Tuesday, January 5th. BidaskClub lowered shares of MEDNAX from a “buy” rating to a “hold” rating in a research note on Thursday, January 7th. Deutsche Bank Aktiengesellschaft lowered shares of MEDNAX from a “hold” rating to a “sell” rating and reduced their price objective for the company from $20.00 to $12.00 in a research note on Monday, October 19th. Finally, ValuEngine upgraded shares of MEDNAX from a “sell” rating to a “hold” rating in a research note on Wednesday, September 16th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $18.42.

MEDNAX Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

Recommended Story: How does equity income fit into an investing strategy?

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.